ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PBH vs RCUS // 10Y YIELD & FRED MACRO BETA

Prestige Consumer Healthcare Inc. (NYSE) VS. Arcus Biosciences Inc. (NYSE) • 15-METRIC TALLY: PBH 7 — RCUS 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PBH VS. RCUS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PBH RCUS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 54.70% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 13.80% -35.00% +48.80 PBH /roic <GO>
EV/EBITDA & P/E Valuation 7.0x — — TIE /valuation <GO>
Free Cash Flow Yield 10.67% -20.42% +31.09 PBH /fcf-yield <GO>
Operating Margin 28.40% -60.00% +88.40 PBH /operating-margins <GO>
Net Profit Margin 17.50% -60.00% +77.50 PBH /net-margins <GO>
Revenue Growth (YoY) -4.30% -35.30% +31.00 PBH /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 2.21 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 1/9 +5.00 PBH /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 52.5 33.1 +19.40 PBH /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 11.3x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.31B $2.37B -$60.2M RCUS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PBH REV RCUS REV PBH GROSS % RCUS GROSS % PBH FCF RCUS FCF
FY 2025 $1.09B $33.0M 54.7% — $246.4M -$484.0M
FY 2024 $1.14B $51.0M 55.8% — $243.3M -$176.0M
FY 2023 $1.13B $37.0M — — $248.9M -$306.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PBH // BETA —
RCUS // BETA —